Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

XB596, a promising bis-naphthalimide anti-cancer agent

S F Chen1, D L Behrens, C H Behrens

  • 1Cancer Research Group, Du Pont Merck Pharmaceutical Company, Glenolden Laboratory and Experimental Station, PA 19036.

Anti-Cancer Drugs
|August 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Association between long-term cumulative levels of non-high-density lipoprotein cholesterol and the risk of cardiovascular disease: a prospective cohort study].

Zhonghua yi xue za zhi·2026
Same author

[Resolving the diagnostic dilemma of gastroesophageal reflux disease: multimodal integration strategies and novel perspectives for precision assessment].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2025
Same author

[Impact of six lipid parameters on cognitive impairment in the elderly Chinese population: a prospective cohort study].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

[Transcatheter edge-to-edge repair strategies for mitral commissural prolapse: a single-center experience].

Zhonghua xin xue guan bing za zhi·2025
Same author

[Clinical characteristics and prognosis of type 1 infratentorial superficial siderosis].

Zhonghua yi xue za zhi·2025
Same author

[Association between cumulative body mass index exposure and cognitive function among elderly people aged 60 years and older in China].

Zhonghua yi xue za zhi·2024

A novel bis-naphthalimide compound, XB596, shows potent anti-tumor activity against various cancer cells, including drug-resistant lines. This DNA-targeting agent demonstrates significant efficacy in preclinical models of solid tumors.

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Bis-naphthalimide derivatives represent a promising class of anti-tumor agents.
  • Developing novel chemotherapeutics is crucial for overcoming drug resistance and improving patient outcomes.

Purpose of the Study:

  • To synthesize and evaluate the anti-tumor potential of a novel bis-naphthalimide compound, XB596.
  • To investigate the mechanism of action and in vivo efficacy of XB596 against various cancer models.

Main Methods:

  • In vitro cytotoxicity assays against human and murine cancer cell lines.
  • Human tumor colony-forming assay for patient-derived tumors.
  • Assessment of DNA incorporation inhibition, DNA damage, and DNA binding using biochemical assays.
  • In vivo anti-tumor efficacy studies using xenograft models in nude mice.

Related Experiment Videos

Main Results:

  • XB596 exhibited potent in vitro growth inhibitory activity (IC50: 7.2-147.5 nM) against diverse cancer cell lines, including doxorubicin-resistant ones.
  • The compound showed cytocidal activity against 23 of 25 patient-derived tumors.
  • XB596 inhibited nucleic acid synthesis, induced DNA single-strand breaks, and acted as a DNA intercalator.
  • In vivo studies demonstrated good anti-tumor activity against human solid tumor xenografts.

Conclusions:

  • XB596 is a potent anti-cancer agent with a DNA-intercalating mechanism of action.
  • The compound shows significant preclinical efficacy against solid tumors, warranting further investigation.